AcquiredStartups
Biggest in a16z Bio+Health
Investor

a16z Bio+Health

1Exits tracked$2.2bnDisclosed value$2.2bnMedian price0Acquihires

Startups backed by a16z Bio+Health that were acquired: 1 exit so far, with the buyer, the price where disclosed and every source.

Photo: Quintin Soloviev / Wikimedia Commons, CC BY 4.0
Healthtech & bio · Austin

Johnson & Johnson to buy eye-drug startup Ollin Biosciences for $2.2 billion upfront

Founded in 2023, Ollin could fetch up to about $3.3 billion with milestones, while Blackstone has agreed to pay $750 million toward the Phase 3 trials of its lead drug.

Price$2.2bnRaised$430mLast stageSeries BBuyer typeCorporate
Latest in a16z Bio+HealthMore stories here soon.